An Open, Single-Center, Single Arm Trial to Evaluate the Efficacy and Safety of Dose Escalation of Icotinib in Advanced NSCLC Patients After Routine Icotinib Therapy.
Phase of Trial: Phase IV
Latest Information Update: 30 Sep 2014
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Zhejiang Beta Pharma
- 13 Feb 2014 Planned End Date changed from 1 Nov 2013 to 1 Feb 2014 as reported by the ClinicalTrials.gov record.
- 13 Feb 2014 Status changed from recruiting to completed as reported by the ClinicalTrials.gov record.
- 03 Jul 2013 Planned number of patients changed from 30 to 35 as reported by ClinicalTrials.gov.